Emerging SARS-CoV-2 Mutations webinar available on-demand

As we learn more about the contribution of genetic and genomic factors to the origin, natural history, and treatment of human disease, clinicians are assuming more responsibility for ordering genetic tests for their patients. This, plus the emergence of Precision Medicine and the growing availability of direct-to-consumer genetic tests, adds to the need for clinicians to understand available tests and how to use them. Increasingly often, health care professionals are expected to:

Cure rates for children with cancer have increased dramatically over the past 40 years with the advent of modern treatment strategies, but most patients have serious life-long medical conditions as a result of the toxicity of their treatments. Clonal hematopoiesis of indeterminate potential (CHIP) is a recently described entity that has been associated with chronic diseases, most notably coronary artery disease. To determine if the presence and features of CHIP are different in childhood cancer survivors compared to age and sex-matched controls, we performed targeted single-cell DNA sequencing of thousands of mature and progenitor hematopoietic cells from a cohort of patients that are greater than 50 years of age and received greater than 25g/m2 of highly mutagenic alkylating chemotherapy as a child.

For most of humanity’s existence, we had only one way to make babies. The last century or so have seen the beginnings of change, with artificial insemination, in vitro fertilization, and prenatal and preimplantation genetic testing. The rest of this century will see astonishing changes, made both possible and attractive by genomics – from embryo selection to embryo editing, from mitochondrial transfer to human reproductive cloning, to in vitro gametogenesis, and beyond. This talk will survey those changes and point out some of their likely ethical, legal, and social implications.

SCIEX’s next-generation Biologics Explorer software is an innovative platform for the comprehensive and deep characterization of biologics. A suite of five built-in workflows, optimized for CID and EAD data, offers powerful and intuitive automated data processing for intact mass and peptide mapping.